

Clinical Trials and Translational Research Advisory Committee
Translational Research Strategy Subcommittee
2019 - present

Nancy E. Davidson, M.D.

TRSS Mission

Survey scientific horizons broadly and provide broad advice to NCI's advisory boards (BSA, CTAC, and NCAB) and NCI leadership on enhancing and broadening the overall translational research portfolio.

- Identify the most provocative and impactful translational research questions
- Examine and identify the most important opportunities for application of new technologies to translational research
- Identify translational research knowledge gaps

TRSS Membership (2019 – present)

Co-Chairs: Chi V. Dang (BSA, former) & Nancy E. Davidson (CTAC & BSC)

Members:

- Francis Ali-Osman (NCAB)
- Walter J. Curran (CTAC, former)
- David A. Mankoff (CTAC, former)
- Lynn M. Matrisian (CTAC)
- Roman Perez-Soler (CTAC)
- Kevin M. Shannon (BSA)
- David A. Tuveson (BSA)
- Kevin P. White (BSA)
- Max S. Wicha (NCAB)

Ex Officio Member:

- James H. Doroshov

Executive Secretary:

- Peter Ujhazy

TRSS Working Groups

Glioblastoma

Co-Chairs:

- Walter J. Curran, Jr., M.D.
- Chi V. Dang, M.D., Ph.D.

Radiation Oncology

Co-Chairs:

- Adam Dicker, M.D., Ph.D.
- Silvia Formenti, M.D.

Gastric and Esophageal Cancer (in process)

- July 2019 Report

- November 2020 Report

Report Hyperlinks:

GBM Report: https://deainfo.nci.nih.gov/advisory/ctac/0719/Att_12_GBM%20WG%20Final%20Report%20CTAC%207-17-19_v1.pdf

Rad Onc Report: <https://deainfo.nci.nih.gov/advisory/ctac/1120/RadOncWGreport.pdf>

TRSS Meeting – March 29, 2021

- Topic - Resistance to immunotherapy
- Research gaps and opportunities
 - Preclinical models
 - Combination immunotherapies
 - Molecular mechanisms, genetics, and cellular basis of response and resistance to immunotherapy
 - Identification and validation of biomarkers of response and resistance to immunotherapy

TRSS Suggestions for Immunotherapy Research Priorities

- Development of better in vivo and in vitro IO preclinical models
 - Immunocompetent murine models (e.g., GEMM, syngeneic tumor models)
 - Human organoid models
- Other immunotherapy research priorities
 - Development of better IO predictive biomarkers
 - Use of imaging methods to develop biomarkers
 - Study of long-term responders
 - Microbiome and tumor microenvironment studies
 - Better understanding of cellular and molecular mechanisms

TRSS Meeting – June 17, 2021

- Topic - Assessment of the Translational Potential of Organoid Cultures and Animal Tumor Models
- Research gaps and opportunities
 - In vivo and in vitro IO preclinical models (GEMM, syngeneic, PDX, humanized mouse)
 - Modeling the key role of the tumor microenvironment
 - Individualized precision oncology models to determine which agents work best for patients
 - Models for preclinical drug discovery phase
 - Multiple conceptual, technical, and administrative barriers to the advancement of preclinical models

TRSS Recommendation

- Workshop to address general principles of models and personalized predictive models
- Robust discussion with experts from the field

TRSS Upcoming Meetings

- Future Meeting dates
 - Thursday, September 9, 11:00 a.m. – 12:00 p.m. ET
 - Thursday, December 16, 3:00 p.m. – 4:00 p.m. ET

Proposed Motions for CTAC

Proposed Motion:

Accept the TRSS meeting summaries from March 29, 2021 and June 17, 2021



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol